Our objective was to review recent developments in diagnosis, staging, and treatment of esthesioneuroblastoma (ENB)
In patients with metastases in cervical lymph nodes (on average 5% of the total) survival was 29%, compared with 64% for patients with N0 disease (odds ratio 5.1). Survival according to treatment modalities was 65% for surgery plus radiotherapy, 51% for radiotherapy and chemotherapy, 48% for surgery, 47% for surgery plus radiotherapy and chemotherapy, and 37% for radiotherapy alone. The histopathological grading according to Hyams and the presence of cervical lymph-node metastases emerged as prognostic factors. A combination of surgery and radiotherapy seems to be the optimum approach to treatment. The exact role of chemotherapy in treatment protocols is still unclear. The role of elective neck dissection is unclear.
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Esthesioneuroblastoma (ENB) is an uncommon malignant neoplasm of the nasal vault, believed to arise from the olfactory epithelium. The tumour was first described in 1924 by Berger and colleagues, and given the name esthésioneuroépithéliome olfactif. 1 Uncertainty about the precise histological origin has led to the use of various names for this tumour, but the only two terms used in recent publications are esthesioneuroblastoma and olfactory neuroblastoma.
Just as there are differing views about the most appropriate name for this unusual tumour, there are many opinions about its origin, diagnosis, and management. The controversy arises primarily from the fact that almost no individual clinician or even institution will treat more than a few patients a year with this diagnosis. Three other factors contribute to the controversy. 2 First, the tumour shows varying biological activity, ranging from indolent growth, with patients surviving with known tumour for more than 20 years, to a highly aggressive neoplasm, capable of rapid widespread metastasis with survival limited to a few months. Second, ENB is easily confused with other undifferentiated neoplasms of the nasal cavity. Third, no universally accepted staging system is available. Kadish and coworkers were the first to propose a staging classification, of three categories, for ENB. 3 Group A is limited to tumours of the nasal fossa; in group B extension is to the paranasal sinuses; group C is defined as extension beyond the paranasal sinuses. Recognising the many shortcomings of this staging system, we proposed a classification based on the more familiar TNM system ( Figure 1 ; Table 1) . 2 The staging can be accomplished before treatment and is largely based on computed tomography (CT) and magnetic resonance imaging (MRI), which are quite reliable in assessing the anatomical extent of disease. Therefore, patients given primary or preoperative radiotherapy can be staged as reliably as those who are candidates for surgery. Although this classification system has gained popularity, [4] [5] [6] various attempts have been made to modify the Kadish system for ENB. 7, 8 Within the past decade, there has been progress in identifying the origin of ENB, which should lead to more precise diagnosis. In addition, although surgery and radiotherapy have remained the main treatments, chemotherapy has been increasingly used. Because of the rarity of this disease, a meta-analysis approach to comparison of treatment modalities could be helpful. The purpose of this paper is to provide such a statistical analysis and to assess recent developments through a systematic review.
Methods
Because of the small number of patients, Hyams' histopathological grades (Table 2; Figure 2 ) are commonly analysed in two groups (grades I and II versus grades III and IV). Since in most cases data were reported in this way only, we also used this grouping. Outcome according to the clinical staging of the Kadish, as well as the DulguerovCalcaterra classifications, were tabulated, but not statistically analysed because present meta-analysis statistical methods are geared to comparison of two groups.
The treatment modalities used were surgery alone; surgery and radiotherapy; radiotherapy alone; a combination of surgery, radiotherapy, and chemotherapy; radiotherapy and chemotherapy; surgery and chemotherapy; and chemotherapy alone. Only the original treatment modality was considered, independently of any salvage therapy for recurrence. Because of the small number of patients, the sequence of treatments was not taken into account. Statistical analysis compared the different treatment modalities against the approach with the highest average survival (surgery and radiotherapy). Because few patients had chemotherapy alone or with surgery, statistical analysis was not done for these two groups.
The type of recurrence (local, regional, or distant) was tabulated overall, since the exact site of first recurrence was not available in all publications.
Data were tabulated in a spreadsheet for basic calculations, averages, and standard deviations. They were arranged to correspond to a contingency table: for example, in comparing the survival of patients treated with surgery versus those treated with surgery and radiotherapy, the numbers of surviving and deceased patients for each treatment modality were calculated for each study. This approach was used for all pairs of variables that were statistically compared. Statistical evaluation of the data was done with the MetaWin software (version 2; Sinauer, Sunderland, MA, USA). 91 The two-by-two contingency data algorithm was used for all variables to calculate the effect size and variance of the odds ratio for each study. The cumulative size effect of the odds ratio across all studies was used to assess the significance of differences between pairs of variables. Fixed and random effects calculations were done, but only the more conservative random effects calculation was used for the statistical evaluation. Data are presented as odds ratios.
The total heterogeneity among studies was assessed by calculation of the sum of the weighted difference between 
Search strategy and selection criteria
The MEDLINE database was searched with the combination 'esthesioneuroblastoma' and 'olfactory neuroblastoma', from 1990 to 2000, without language tags. The search was supplemented by cross-checking of the references in each publication. Among the 242 articles retrieved, we excluded 53 that did not report directly on ENB cases, 12 that dealt with radiology issues, ten reviews on ENB, and 13 reviews of treatments for base-of-skull neoplasms of mixed histology. We arbitrarily decided to include only articles reporting on five or more cases, further excluding 88 references. Finally, nine publications were excluded because the language of the article was not English, French, German, Italian, or Spanish. The remaining 57 publications constitute the basis of this review. These were supplemented by another 19 relevant publications found in references cited. 4, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] The studies were divided into three types, according to their principal objectives: origin and aetiology of ENB, 9, 11, 15, [17] [18] [19] 21, 24, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] histopathological diagnosis; 10,12-14,23,37,41-53 and treatment. 2, [4] [5] [6] [7] [8] 16, 20, 22, 25, 26, 43, The remaining 14 cited publications are of historical interest 1, 3, [79] [80] [81] [82] [83] [84] or concern ENB indirectly, [85] [86] [87] [88] [89] [90] and they were not directly used in the data analysis.
Studies on the origin, aetiology, and histopathological diagnosis were reviewed subjectively and summarised in the discussion.
Among the 37 treatment studies, analysis was restricted to 26 because seven articles were repeated reports probably on the same patients, 16, 59, 61, 67, [74] [75] [76] and four 20, 22, 25, 26 only covered specific aspects of the treatment of ENB. Data extracted from the studies were the total number of patients, the staging system used, the patients' distribution by stage and by histological grade, and the type of treatment. Outcome data consisted of recurrence-free survival at 3 years and 5 years, overall survival at 5 years and 10 years, and the results by stage, grade, and treatment modality. For data on grading, staging, and treatment, at least 2-year disease-free survival was used. The studies were selected and data extracted independently by two authors. Differences were reconciled through discussion.
individual and total size effects 92 and compared with the 2 distribution. Publication bias was assessed graphically by examining funnel plots, weighted histograms, and normal quantile plots, as well as by rank correlation tests (Kendall's tau and Spearman's rho) between the effect size and the study size.
Results
The The distribution was 12% stage A, 27% stage B, and 61% stage C. Mean survival for these three groups was 72% (SD 41), 59% (SD 44), and 47% (SD 16), respectively. Four studies 2,4-6 used the Dulguerov and Calcaterra staging with the following distribution: 25% T1, 25% T2, 33% T3, and 17% T4. Mean survival was 81% (SD 17) for T1, 93% (SD 14) for T2, 59% (SD 33) for T3, and 48% (SD 41) for T4 patients.
On average 5% (SD 7) of patients presented with cervical lymph-node metastases. In the studies with survival data according to the N stage, 2, 8, 60, 61, 64, 69, 78 only 29% of nodepositive patients were treated successfully, compared with 64% of N0 patients, a significant difference (odds ratio 5.1 [95% CI 1.6-17.0]).
Information on the treatment modalities used were available in all the studies. For each treatment modality, the number of patients, the distribution in terms of frequency, and survival are shown in Table 3 . The combination of surgery and radiotherapy was the most frequently used treatment (44%); it was associated with the best average survival results (65%) and therefore statistical analysis assessed differences between this combination and other treatment modalities. The only significant difference was for radiotherapy as sole treatment (odds ratio for death 2.5 [95% CI 1.0-6.0).
Local recurrence was found in 29% (SD 16) of patients on average, with successful salvage in a third of cases. Regional recurrence occurred in 16% (SD 15) of patients with successful salvage in 27%. Distant metastases were found in 17% (SD 14) of patients. None of the statistical comparisons evaluated was associated with significant heterogeneity or publication bias.
Discussion and review
ENB remains a rare disease. Skolnik and colleagues were able to find only about 100 reported cases in the world 79 More recently, in an extensive review of published studies, 36 Broich and colleagues found about 1000 new cases reported. The majority of these (80%) have been reported during the past 20 years, almost certainly owing to better recognition of this disease entity by pathologists, although the possibility of a rising incidence cannot be entirely ruled out.
Origin
The exact cell of origin of ENB is controversial. Proposed sources include Jacobson's vomeronasal organ, the sphenopalatine ganglion, the ectodermal olfactory placode, Loci's ganglion, autonomic ganglia in the nasal mucosa, and the olfactory epithelium. 36 Although a neuronal or neural crest origin is supported by the presence of neurofilaments in ENB, 11 until recently, 33 little evidence linked ENB directly to the olfactory epithelium.
The olfactory neuroepithelium is a unique neurosensory organ, because olfactory neurons are continuously replaced throughout adult life. 81, 82 Three types of cells are classically recognised in the olfactory epithelium: the basal cells, located against the basement membrane; the olfactory neurosensory cells; and the sustentacular supporting cells, the processes of which extend onto the luminal surface. The spherical basal cells constitute a stem-cell compartment, which confers to this tissue its peculiar ability to regenerate not only physiologically but also when damaged by trauma or environmental insults. 17, 19 The basal cells express 15 neural cell adhesion molecule (NCAM) 87 and the mammalian homologue of Drosophila achaete-scute (MASH) gene. 88 These progenitor cells differentiate into olfactory neurosensory cells, which show progressive maturation from the basal membrane to the epithelial surface. 19, 24 Each layer can be characterised by olfactory-specific and neuronspecific markers. Immature olfactory cells express 17, 19 GAP43, a 24 kDa membrane-associated protein kinase C involved in turnover of polyphosphoinositide. 86 As these cells mature, they grow axons to the olfactory bulb and migrate towards the surface; they express olfactory marker protein 80 and NCAM, but not GAP43. 17, 19, 24 In the mid 1990s, 33 ENB tumours were found to express HASH, the human homologue of the MASH gene, but stained negative for olfactory marker protein. So far, HASH has only been shown in medullary thyroid carcinoma and certain small-cell lung carcinomas. 21 Further indirect evidence that ENB originates from olfactory stem cells comes from transgenic mice, in which the SV40T oncogene was inserted under control of the olfactory marker protein gene promoter region; 32 these mice did not develop ENB but adrenal and sympathetic ganglia neuroblastoma. Therefore, the currently available evidence links ENB with the basal progenitor cells of the olfactory epithelium.
Inclusion of ENB within the Ewing's sarcoma family of tumours 35 or the primitive neuroectodermal tumours (PNET) 34 has been proposed, 30 because of the identification in some cases of translocation t (11:22) , which is regarded as specific for Ewing's sarcoma. 89 Studies with fluorescence in situ hybridisation 39, 40 and RT-PCR 31, 40 have not confirmed this translocation in ENB. ENB should therefore be seen as a distinct entity from PNET and the Ewing's sarcoma family of tumours.
No clear aetiological agent or exposure has been documented in human beings. However, ENB can be consistently induced by nitrosamine compounds in rodents. 9, 18, 38 In cats with spontaneous ENB or transgenic mice developing ENB, 27 type C retroviral particles have been demonstrated and classified as, respectively, feline and murine leukaemia viruses. The role of retroviral sequences in human ENB remains unclear.
Histopathological diagnosis
The diagnosis of ENB by light microscopy is not difficult when the tumour is well differentiated and consists of Review Esthesioneuroblastoma 49 The differential diagnosis includes malignant melanoma, embryonal rhabdomyosarcoma, malignant lymphoma, extramedullary plasmocytoma, and, in particular, sinonasal undifferentiated carcinoma and sinonasal neuroendocrine carcinoma. In these instances, immunohistochemical staining and electron microscopy become important in establishing the diagnosis. There is no specific immunocytological stain for ENB, but a typical staining profile can be very helpful. The tumour is positive for S-100 protein neurofilaments, 41 but most cases are negative for cytokeratin, desmin, vimentin, actin, glial fibrillary acidic protein, UMB45, and common leucocytic antigen. 13, 34, 41, 43 ENB are also positive for chromogranin and synaptophysin. If special stains are not helpful, electron microscopy can be reliable in visualising uniform round nuclei, dense core neurosecretory granules with diameters of 125-350 nm, neuronal processes containing microtubules and neurofilaments, and rare synapses. 12, 48 Distinction of ENB from melanoma is based on the lack of expression of UMB45 antigen and the pattern of S-100 staining. In melanoma, S-100 protein stains most cells strongly, resulting in a diffuse and strong immunopositivity, whereas in ENB the stain is scattered and peripheral. ENB can be distinguished from rhabdomyosarcoma by the lack of cross-striated cells (rhabdomyoblasts) and absence of desmin, vimentin, and actin expression. Differentiation of ENB from lymphoma is based on the lack of common leucocyte antigen immunostaining. Most sinonasal lymphomas are non-Hodgkin diffuse large-cell tumours, and many have a B-cell phenotype.
Sinonasal undifferentiated carcinoma was initially described by Frierson and colleagues in 1986. 85 Numerous mitotic figures, areas of necrosis, vascular invasion, and lack of glandular differentiation should aid the differential histopathological diagnosis. The immunohistochemical differentiation from ENB is based on a positive stain with cytokeratin antibodies. Recently, these tumours were found to be positive by in situ hybridisation for Epstein-Barr virus RNA. 53 This highly malignant lesion should be distinguished from ENB and needs aggressive treatment, which should probably include chemotherapy. 23 Another aggressive neoplasm that must be distinguished from ENB is neuroendocrine sinonasal carcinoma, as originally suggested by Silva and colleagues. 10 Cytokeratin immunopositivity, especially in a punctate paranuclear distribution is the main diagnostic marker for differentiation from ENB. 51 Electron microscopy may be useful in demonstrating junctional complexes and tonofilaments.
Ewing's sarcoma seems difficult to distinguish from poorly differentiated ENB, and cases of Ewing's sarcoma within the paranasal sinuses, although rare, do occur. 39 With the use of monoclonal antibodies to myc-2 protein, a specific and sensitive marker of Ewing's sarcoma, 90 ENB can be differentiated from Ewing's sarcoma, because ENB tumours do not stain. This marker should therefore be included in the diagnostic tests for ENB.
In summary, the pathological distinction of poorly differentiated small neoplasms of the nasal cavity is difficult and is based on the results of antigen expression of a panel of antibodies by immunohistochemistry and, if necessary, electron microscopy. The reactions used should include S-100 protein, chromogranin, synaptophysin, or both, cytokeratin, desmin, actin, UMB45, common leucocyte antigen, and myc-2 protein. The demonstration by RT-PCR of HASH expression, 33 although still investigational, could become the diagnostic procedure of choice.
There is a lack of consensus on prognostic histological features. Support for the prognostic value of Hyams and coworkers' grading 14 has been published. 61 Hirose and colleagues 47 found that a high degree of S-100 immunopositivity and a low (<10%) Ki-67 labelling index (a marker for proliferation) were associated with better survival. There are conflicting data on the prognostic role of the P53 tumour suppressor gene mutations.
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Clinical data
There have been no precise epidemiological studies, but our unpublished data suggest that ENB represents about 5% of all nasal malignant tumours. ENB affects male and female patients with similar frequency and can be found in all agegroups. 2, 36 There is no specific symptom for ENB, as for most nasal and paranasal malignant diseases. 2 The average delay between the appearance of the first symptom and the diagnosis is 6 months. 2 The commonest symptoms are a unilateral nasal obstruction (70%), followed by epistaxis (46%). 2, 8 However, these symptoms occur in common nasal diseases such as chronic rhinosinusitis or allergic polypoid sinus disease. The key to early diagnosis of ENB is early referral for an intranasal biopsy. We think that a unilateral nasal obstruction or recurrent epistaxis lasting more than 1-2 months should be thoroughly investigated by an otolaryngologist, although the cost-effectiveness of this approach has not been assessed.
Fine-cut CT scan (3 mm slice thickness) with direct coronal imaging is the initial radiological study of choice (Figure 3) . ENB, which does not have a specific radiological appearance, is seen as a homogeneous soft-tissue mass in the nasal vault, with uniform and moderate contrast enhancement. CT images are essential for correct staging and should be carefully examined for erosion of lamina papyracea, cribriform plate, and fovea ethmoidalis.
Since nasal secretions, which tend to accumulate behind an obstruction, are difficult to differentiate from tumour tissue by CT scan, MRI is often also necessary. ENB appears as hypointense to grey matter on T1-weighted images and isointense or hyperintense on T2-weighted images. MRI also demonstrates better an intraorbital or an intracerebral extension. When an intracerebral extension is found, marginal cysts have been seen radiologically in a few cases. 22 Because details of bony erosion are better shown on CT images, both studies are required in the majority of patients.
Treatment
A combination of surgery and radiotherapy is the most frequently used approach, and the one achieving the highest cure rates. Despite the lack of support for single-modality treatment regimens, 54 a substantial number of patients are treated by surgery or radiotherapy alone. The difference in survival between the combined treatments and radiotherapy alone is significant (Table 3) . Although surgery alone, a combination of radiotherapy and chemotherapy, and triplemodality treatment (surgery, radiotherapy, and chemotherapy) were associated with lower survival, with differences of 15-20%, the differences from the best combination were not significant, probably because of the limited number of patients.
Therefore the only conceivable indication for singlemodality treatment would be a patient with a small tumour located well below the cribriform plate (T1 stage). Unlike most surgical specimens in the head and neck, specimens of the nasal cavity and paranasal sinuses, even en bloc, are difficult to orient and surgical margins difficult to analyse. Because one can rarely be completely confident of the adequacy of surgical margins, postoperative radiotherapy seems justified in almost all patients to keep the risk of local recurrence to a minimum.
Most institutions favour surgery as the first treatment modality, followed by radiotherapy. 2, 4, 61, 63 The theoretical advantage that preoperative radiotherapy will reduce an unresectable tumour to a resectable size has never been clearly demonstrated. 64 Standard radiotherapeutic techniques include external megavoltage beam and a three-field technique; an anterior port is combined with wedged lateral fields to provide a homogeneous dose distribution. The dose ranges from 5500 cGy to 6500 cGy and in most cases is above 6000 cGy. Possible roles of proton beam radiotherapy and stereotactic radiotherapy have been suggested, 25 but remain to be convincingly demonstrated.
Endocranial extension and close relation to the ethmoid roof and cribriform plate requires a combined transfacial and neurosurgical approach. A craniotomy is probably not justified for T1 tumours where there is clear radiological evidence of a normal cribriform plate and upper ethmoid cells. All other patients should be managed by a transfacial approach combined with a bifrontal craniotomy. In our experience, craniofacial resection results in much better local control than other surgical resections (100% versus 40% ). 2 At the University of Virginia, the recurrence rate was 60% before the adoption of craniofacial resection compared with 40% afterwards. 16 Craniofacial resection permits en bloc resection of the tumour with better assessment of any intracranial extension and protection of the brain and optic nerves. The resection should include the entire ipsilateral cribriform plate and cristagalli. The olfactory bulb and overlaying dura should be removed with the specimen. Preservation of the contralateral olfactory system, when possible, has resulted in preserved sense of smell in a few cases. Tumour that does not penetrate the orbit can be encompassed by resecting the lamina papyracea or even small segments of orbital periosteum.
Early reports on chemotherapy in ENB focused on patients with recurrent or metastatic disease. 83, 84 Neoadjuvant chemotherapy has been advocated 5, 64 for patients with advanced disease. At the University of Virginia, patients with Kadish stage C disease are first treated with two cycles of cyclophosphamide (300-650 mg/m 2 ) and vincristine (1-2 mg) with or without doxorubicin, followed by 50 Gy of radiotherapy, which is then followed by craniofacial resection. 64 With this regimen the 5-year actuarial survival is 72% and that at 10 years 60%. Similar results have been obtained without chemotherapy, 2 and the extent to which chemotherapy contributed to the cure rates is unclear. Cisplatin-based regimens are preferred at the Mayo Clinic and at the Gustave-Roussy Institute. 8, 74 Although ENB responds to cisplatin, "chemotherapy for high-grade tumours in the advanced setting is not curative". 74 At Harvard, the preferred regimen is cisplatin (33 mg/m 2 daily) and etoposide (100 mg/m 2 daily) for 3 days. 5 This has been followed by proton radiation in nine patients, with excellent results. That study is probably the only one that shows convincingly the possibility of a nonsurgical treatment of ENB, although the number of patients is small and the follow-up short.
Neck metastases are found at presentation in 5% of patients. Such patients should be treated by neck dissection or radiotherapy. Some see the frequency of delayed neck metastasis (16%) as an indication for elective neck dissection in all cases of ENB. Probably patients with advanced local disease should undergo radiological examination of the neck and may become candidates for regional treatment. 20 
Prognosis
Treatment results before the availability and use of modern diagnostic techniques were probably flawed by the inclusion of cases of sinonasal undifferentiated carcinoma and sinonasal neuroendocrine carcinoma. Although the metaanalysis found a 5-year survival of 45%, most large studies quoted survival around 70%. 2, 6, 7, 64 The most frequent recurrence is local, with rates around 30%. 7, 8, 64 Craniofacial resection followed by radiotherapy seems to result in fewer recurrences -around 10%.
2,61 Salvage after local recurrence is possible in 33-50% of cases. Regional recurrence, when the primary site is under control, occurs in 15-20% of cases 2, 4, 7, 36, 64 and is salvageable by further treatment in a third of cases. Distant metastases with locoregional control are not very common (8% 64 ) and carry a very poor prognosis. The meta-analysis data confirm those of Koka and colleagues 8 on the presence of palpable lymph nodes as one of the most important prognostic factors for survival (29% with nodes, 64% without). Hyams' histopathological grading should also be regarded as an important prognostic factor, as previously suggested. In addition, tumour shrinkage after chemotherapy has been correlated with survival. 74, 75 We emphasise that recurrence can occur years after the completion of treatment, even more than 10 years later. 2, 7, 64 Therefore, long-term follow-up is needed, although the exact frequency of visits and the necessity for radiological studies have not been precisely studied.
